Aktuální možnosti biologické léčby u axiálních spondyloartritid
| Authors | |
|---|---|
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | Farmakterapeutikcká revue |
| MU Faculty or unit | |
| Citation | |
| Keywords | axial spondyloarthritis biological disease modifying antirheumatic drugs IL-17 inhibition, TNF-a inhibitors |
| Description | Therapy of axial spondyloarthritis is a complex task. The major target in the treatment is suppression of inflammation, reducing clinical symptoms of disease and preventing structural progression. An integral part of the therapy is the extra-articular manifestations occurring in a large number of patients. Regular exercises in combination with non-steroidal anti-inflammatory drugs are the basis for therapy, and in case of insufficient effect, biological therapy is indicated. For more than a decade, the only option of biological treatment was TNF-a blockade. The portfolio of biologic drugs for axial spondyloarthritis has recently expanded the fully human monoclonal antibody against IL-17A, secukinumab. All 5 TNF-a inhibitors and secukinumab can be used to treat the radiographic form of the disease, there are some differences in efficacy of TNF-a inhibitors in treatment of extra-skeletal manifestations. The expanding spectrum of biological therapy is thus a therapeutic option that makes remission of the disease a real goal. |